1. Home
  2. SNDL vs TECX Comparison

SNDL vs TECX Comparison

Compare SNDL & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SNDL Inc.

SNDL

SNDL Inc.

HOLD

Current Price

$1.51

Market Cap

386.3M

Sector

Health Care

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$33.31

Market Cap

393.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDL
TECX
Founded
2006
2019
Country
Canada
United States
Employees
N/A
51
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
386.3M
393.0M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
SNDL
TECX
Price
$1.51
$33.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$5.00
$80.40
AVG Volume (30 Days)
961.4K
380.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.09
N/A
Revenue Next Year
$2.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$13.70
52 Week High
$2.89
$35.99

Technical Indicators

Market Signals
Indicator
SNDL
TECX
Relative Strength Index (RSI) 44.57 67.84
Support Level $1.44 $16.83
Resistance Level $1.60 $35.99
Average True Range (ATR) 0.07 2.81
MACD 0.00 0.91
Stochastic Oscillator 21.05 80.72

Price Performance

Historical Comparison
SNDL
TECX

About SNDL SNDL Inc.

SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: